Literature DB >> 34416976

Preparing for the NASH Epidemic: A Call to Action.

Fasiha Kanwal1, Jay H Shubrook2, Zobair Younossi3, Yamini Natarajan4, Elisabetta Bugianesi5, Mary E Rinella6, Stephen A Harrison7, Christos Mantzoros8, Kim Pfotenhauer9, Samuel Klein10, Robert H Eckel11, Davida Kruger12, Hashem El-Serag4, Kenneth Cusi13.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are common conditions with a rising burden. Yet there are significant management gaps between clinical guidelines and practice in patients with NAFLD and NASH. Further, there is no single global guiding strategy for the management of NAFLD and NASH. The American Gastroenterological Association, in collaboration with 7 professional associations, convened an international conference comprising 32 experts in gastroenterology, hepatology, endocrinology, and primary care providers from the United States, Europe, Asia, and Australia. Conference content was informed by the results of a national NASH Needs Assessment Survey. The participants reviewed and discussed published literature on global burden, screening, risk stratification, diagnosis, and management of individuals with NAFLD, including those with NASH. Participants identified promising approaches for clinical practice and prepared a comprehensive, unified strategy for primary care providers and relevant specialists encompassing the full spectrum of NAFLD/NASH care. They also identified specific high-yield targets for clinical research and called for a unified, international public health response to NAFLD and NASH.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  NAFLD; NASH

Mesh:

Year:  2021        PMID: 34416976     DOI: 10.1053/j.gastro.2021.04.074

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  10 in total

1.  AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.

Authors:  Michelle T Long; Mazen Noureddin; Joseph K Lim
Journal:  Gastroenterology       Date:  2022-07-14       Impact factor: 33.883

2.  Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey.

Authors:  Mary Rinella; Donna R Cryer; Amy Articolo; Travis Fisher; Jennifer Schneider; Karl Nadolsky
Journal:  BMC Gastroenterol       Date:  2022-07-10       Impact factor: 2.847

Review 3.  Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.

Authors:  Yi-Wen Shi; Jian-Gao Fan
Journal:  Acta Pharmacol Sin       Date:  2021-12-14       Impact factor: 7.169

Review 4.  Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jay H Shubrook; Leon A Adams; Kim Pfotenhauer; Vincent Wai-Sun Wong; Eugene Wright; Manal F Abdelmalek; Stephen A Harrison; Rohit Loomba; Christos S Mantzoros; Elisabetta Bugianesi; Robert H Eckel; Lee M Kaplan; Hashem B El-Serag; Kenneth Cusi
Journal:  Gastroenterology       Date:  2021-09-20       Impact factor: 33.883

Review 5.  PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.

Authors:  Naomi F Lange; Vanessa Graf; Cyrielle Caussy; Jean-François Dufour
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

6.  Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.

Authors:  Yang Liu; Yiping Li; Jue Wang; Lili Yang; Xiao Yu; Ping Huang; Haiyan Song; Peiyong Zheng
Journal:  BMC Complement Med Ther       Date:  2022-08-09

7.  SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease.

Authors:  Erica Novo; Andrea Cappon; Gianmarco Villano; Santina Quarta; Stefania Cannito; Claudia Bocca; Cristian Turato; Maria Guido; Marina Maggiora; Francesca Protopapa; Salvatore Sutti; Alessia Provera; Mariagrazia Ruvoletto; Alessandra Biasiolo; Beatrice Foglia; Emanuele Albano; Patrizia Pontisso; Maurizio Parola
Journal:  Front Immunol       Date:  2022-07-08       Impact factor: 8.786

8.  Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease.

Authors:  Gian Paolo Caviglia; Aurora Nicolosi; Maria Lorena Abate; Patrizia Carucci; Chiara Rosso; Emanuela Rolle; Angelo Armandi; Serena Aneli; Antonella Olivero; Alessandra Risso; Davide Giuseppe Ribaldone; Christian Fermer; Giorgio Maria Saracco; Silvia Gaia; Elisabetta Bugianesi
Journal:  Curr Oncol       Date:  2022-07-31       Impact factor: 3.109

9.  Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Dig Dis Sci       Date:  2022-09-29       Impact factor: 3.487

10.  NAFLD and HCC: Time to Bridge the Gap.

Authors:  George Cholankeril; Fasiha Kanwal
Journal:  Hepatology       Date:  2021-08-30       Impact factor: 17.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.